Preliminary analysis of PD-1 inhibitors combined with chemotherapy as neoadjuvant therapy for local advanced non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the ASCO ...
Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...
About 5% of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, ...
Adjuvant treatment with Alecensa (alectinib) elicited a 4-year overall survival (OS) rate of 98.4% for patients with resected ALK-positive early stage non–small cell lung cancer (NSCLC) according to ...
How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to fight ...
Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a type of ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment ...
Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback